ENANTA PHARMACEUTICALS, INC Net Cash Provided by (Used in) Investing Activities, Continuing Operations
ENANTA PHARMACEUTICALS, INC (ENTA) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of $4.01 million for the 6-month period ending 2018-03-31, per its 10-Q filed 2018-05-10.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2018-05-10
- ENANTA PHARMACEUTICALS, INC net cash provided by (used in) investing activities, continuing operations for the quarter ending 2018-03-31 was $6.46M, a 257.53% increase year-over-year.
- ENANTA PHARMACEUTICALS, INC net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-12-31 was -$2.45M, a 383.01% decline year-over-year.
- ENANTA PHARMACEUTICALS, INC net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-09-30 was -$14.90M.
- ENANTA PHARMACEUTICALS, INC net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-06-30 was $7.66M.
- ENANTA PHARMACEUTICALS, INC net cash provided by (used in) investing activities, continuing operations for fiscal 2017 was -$4.57M.
- ENANTA PHARMACEUTICALS, INC net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was -$43.66M.
- ENANTA PHARMACEUTICALS, INC net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$88.19M, a 17843.66% decline from fiscal 2014.
- ENANTA PHARMACEUTICALS, INC net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was $497.00K.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2018-03-31 | $6.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-05-10 | $4.01M 10-Q · filed 2018-05-10 | -$10.89M derived: sum of 3 quarters · filed 2018-05-10 | -$3.23M derived: sum of 4 quarters · filed 2018-05-10 |
| 2017-12-31 | -$2.45M 10-Q · filed 2018-02-09 | -$17.35M derived: sum of 2 quarters · filed 2018-02-09 | -$9.69M derived: sum of 3 quarters · filed 2018-02-09 | -$7.88M derived: sum of 4 quarters · filed 2018-05-10 |
| 2017-09-30 | -$14.90M derived: 10-K 12 month − 10-Q 9 month · filed 2017-12-11 | -$7.24M derived: sum of 2 quarters · filed 2017-12-11 | -$5.44M derived: sum of 3 quarters · filed 2018-05-10 | -$4.57M 10-K · filed 2017-12-11 |
| 2017-06-30 | $7.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-08-09 | $9.46M derived: sum of 2 quarters · filed 2018-05-10 | $10.33M 10-Q · filed 2017-08-09 | $4.18M derived: sum of 4 quarters · filed 2018-05-10 |
| 2017-03-31 | $1.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-05-10 | $2.67M 10-Q · filed 2018-05-10 | -$3.48M derived: sum of 3 quarters · filed 2018-05-10 | -$34.90M derived: sum of 4 quarters · filed 2018-05-10 |
| 2016-12-31 | $865.00K 10-Q · filed 2018-02-09 | -$5.28M derived: sum of 2 quarters · filed 2018-02-09 | -$36.71M derived: sum of 3 quarters · filed 2018-02-09 | -$37.17M derived: sum of 4 quarters · filed 2018-02-09 |
| 2016-09-30 | -$6.15M derived: 10-K 12 month − 10-Q 9 month · filed 2017-12-11 | -$37.57M derived: sum of 2 quarters · filed 2017-12-11 | -$38.03M derived: sum of 3 quarters · filed 2017-12-11 | -$43.66M 10-K · filed 2017-12-11 |
| 2016-06-30 | -$31.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-08-09 | -$31.88M derived: sum of 2 quarters · filed 2017-08-09 | -$37.52M 10-Q · filed 2017-08-09 | -$33.42M derived: sum of 4 quarters · filed 2017-12-11 |
| 2016-03-31 | -$457.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-05-10 | -$6.09M 10-Q · filed 2017-05-10 | -$1.99M derived: sum of 3 quarters · filed 2017-12-11 | $6.18M derived: sum of 4 quarters · filed 2017-12-11 |
| 2015-12-31 | -$5.63M 10-Q · filed 2017-02-09 | -$1.53M derived: sum of 2 quarters · filed 2017-12-11 | $6.64M derived: sum of 3 quarters · filed 2017-12-11 | -$100.84M derived: sum of 4 quarters · filed 2017-12-11 |
| 2015-09-30 | $4.10M derived: 10-K 12 month − 10-Q 9 month · filed 2017-12-11 | $12.27M derived: sum of 2 quarters · filed 2017-12-11 | -$95.21M derived: sum of 3 quarters · filed 2017-12-11 | -$88.19M 10-K · filed 2017-12-11 |
| 2015-06-30 | $8.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-08-09 | -$99.31M derived: sum of 2 quarters · filed 2016-08-09 | -$92.28M 10-Q · filed 2016-08-09 | -$83.07M derived: sum of 4 quarters · filed 2016-12-09 |
| 2015-03-31 | -$107.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-05-10 | -$100.46M 10-Q · filed 2016-05-10 | -$91.25M derived: sum of 3 quarters · filed 2016-12-09 | -$118.56M derived: sum of 4 quarters · filed 2016-12-09 |
| 2014-12-31 | $7.03M 10-Q · filed 2016-02-09 | $16.24M derived: sum of 2 quarters · filed 2016-12-09 | -$11.07M derived: sum of 3 quarters · filed 2016-12-09 | $6.17M derived: sum of 4 quarters · filed 2016-12-09 |
| 2014-09-30 | $9.21M derived: 10-K 12 month − 10-Q 9 month · filed 2016-12-09 | -$18.10M derived: sum of 2 quarters · filed 2016-12-09 | -$852.00K derived: sum of 3 quarters · filed 2016-12-09 | $497.00K 10-K · filed 2016-12-09 |
| 2014-06-30 | -$27.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-08-10 | -$10.06M derived: sum of 2 quarters · filed 2015-08-10 | -$8.72M 10-Q · filed 2015-08-10 | -$16.35M derived: sum of 4 quarters · filed 2015-12-11 |
| 2014-03-31 | $17.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-05-08 | $18.60M 10-Q · filed 2015-05-08 | $10.96M derived: sum of 3 quarters · filed 2015-12-11 | |
| 2013-12-31 | $1.35M 10-Q · filed 2015-02-06 | -$6.29M derived: sum of 2 quarters · filed 2015-12-11 | ||
| 2013-09-30 | -$7.64M derived: 10-K 12 month − 10-Q 9 month · filed 2015-12-11 | -$69.22M 10-K · filed 2015-12-11 | ||
| 2013-06-30 | -$61.58M 10-Q · filed 2014-08-12 | |||
| 2012-09-30 | -$18.04M 10-K · filed 2014-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |